Compare HP Inc (HPQ) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs 10X Genomics Inc — how do they compare? HP Inc trades at $30.33 (market cap $29.25B), while 10X Genomics Inc trades at $82.5 (market cap $10.07B). The key difference: HP Inc is far larger — about 2.9× 10X Genomics Inc's market cap, and HP Inc pays a 3.7% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 70 Days and 10X Genomics Inc for 92 Days on average.
| HPQ | TXG | |
|---|---|---|
Market Cap | $29.25B | $10.07B |
Volume | 10,025,806 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $35.48 | $97.74 |
52-Week Low | $18.20 | $11.48 |
Typical Hold Time | 70 Days | 92 Days |
Enterprise Value | $35.42B | $9.59B |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $32.24, up 1.61% with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, maintaining stable revenue around $55B with a 4.14% net margin. Recent news highlights HP's new PC launches and AI capabilities, though the stock faces headwinds from a projected mid-single-digit PC market decline in 2027.
The outlook is mixed: valuation appears reasonable with a P/E of 12.38 and P/S of 0.51, and strong cash flow supports dividends. However, negative shareholder equity and competitive pressures in the PC market present risks. Analyst consensus is cautious with a $25.75 price target below current levels, suggesting limited near-term upside.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
